RG
RGN.F Repligen Corporation
- Market cap
- EUR 9.89B
- P/E
- -
- P/B
- 5.38x
- ROE
- -1.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RGN.F undervalued?
Graham numberThe Graham number of Repligen Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Repligen Corporation fundamental analysis
No fundamental analysis for Repligen Corporation yet.
Repligen Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a …
Full company profileRepligen Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Repligen Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 105M | 141M | 194M | 270M | 366M | 671M | 802M | 632M | 634M | 738M | 810M |
| Gross Profit | 57.4M | 74.2M | 108M | 151M | 210M | 391M | 456M | 278M | 275M | 386M | 439M |
| Operating Income | 19.2M | 14.0M | 26.0M | 36.1M | 69.8M | 173M | 196M | 17.1M | -31.9M | 41.6M | 65.7M |
| EBITDA | - | 24.2M | 43.9M | 56.3M | 98.4M | 205M | 220M | 145M | 80.3M | 181M | 104M |
| Net Income | 11.7M | 28.4M | 16.6M | 21.4M | 59.9M | 128M | 186M | 35.6M | -25.5M | 48.9M | -33.5M |
| EPS | - | 0.65 | 0.38 | 0.41 | 1.09 | 2.32 | 3.35 | 0.64 | -0.45 | 0.87 | -0.59 |
| Balance Sheet | |||||||||||
| Total Assets | 289M | 744M | 775M | 1.40B | 1.90B | 2.36B | 2.52B | 2.82B | 2.83B | 2.95B | 2.93B |
| Total Liabilities | 120M | 152M | 159M | 340M | 374M | 608M | 614M | 853M | 857M | 844M | 835M |
| Shareholders' Equity | 169M | 592M | 616M | 1.06B | 65.8M | 1.75B | 397M | 1.97B | 1.97B | 2.11B | 2.09B |
| Cash & Short-term Investments | 122M | 174M | 194M | 528M | 717M | 604M | 523M | 751M | 757M | 566M | 727M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 7.52M | 17.5M | 32.8M | 67.2M | 62.6M | 119M | 172M | 147M | 175M | 117M | 139M |
| Capital Expenditure | 4.33M | 5.45M | 10.6M | 18.5M | 22.5M | 67.1M | 84.8M | 49.3M | 32.9M | 25.7M | 21.7M |
| Free Cash Flow | - | 12.0M | 18.7M | 44.1M | 36.3M | 47.7M | 38.7M | 97.5M | 142M | 91.7M | 117M |
| Ratios | |||||||||||
| ROE | 6.9% | 4.8% | 2.7% | 2.0% | 91.1% | 7.3% | 46.8% | 1.8% | -1.3% | 2.3% | -1.6% |
| ROA | 4.0% | 3.8% | 2.1% | 1.5% | 3.1% | 5.4% | 7.4% | 1.3% | -0.9% | 1.7% | -1.1% |
| Net Profit Margin | 11.2% | 20.1% | 8.6% | 7.9% | 16.4% | 19.1% | 23.2% | 5.6% | -4.0% | 6.6% | -4.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Repligen Corporation dividends
Repligen Corporation has not paid dividends in the last 9 fiscal years.
Who owns Repligen Corporation
- Insiders 4.63%
- Institutions 95.37%
- Public & others 0.00%
- Shares outstanding 63.9M
- Free float 61.0M
Repligen Corporation company profile
- Company name
- Repligen Corporation
- Ticker
- RGN.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,000
- Fiscal year end
- December
- Address
- Building 1, Waltham, MA, United States, 02453
- Phone
- 781 250 0111
- Website
- repligen.com
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Repligen Corporation management
10- Mr. Olivier LoeillotPresident, CEO & Director · born 1970
- Mr. Jason K. GarlandCFO & Chief Compliance Officer · born 1974
- Mr. James R. BylundChief Operating Officer · born 1963
- Mr. Anthony J. HuntAdvisor · born 1964
- Mr. Ralf KuriyelSenior Vice President of Research & Development · born 1958
- Mr. Brian Robb DouglassSenior VP & Chief Product Officer · born 1975
- Dr. Paul R. Schimmel Ph.D.Founder · born 1941
- Ms. Violetta HughesChief Accounting Officer · born 1973
- Ms. Heather EmsChief Information Officer
- Mr. Jacob K. Johnson C.F.A.Vice President of Investor Relations